MAVENIR
20.2.2024 08:01:34 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks, announces new developments on its OpenBeam™ massive MIMO (mMIMO) portfolio, powered by Qualcomm® QRU100 5G RAN platform, in continuation to previous years product launch update. Mavenir expands the OpenBeam™ portfolio by introducing the low-power next-generation 32TRX mMIMO variant along with a high-power 32TRX AAU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240219034877/en/
Mavenir OpenBeam massive MIMO 32TRX Active Antenna Unit. (Photo: Business Wire)
These next-generation mMIMO 32TRX Active Antenna Units (AAUs) introduce a new breed of open and interoperable radios that are green by design. OpenBeam™ mMIMO AAU delivers exceptional energy efficiency – resulting in one of the leanest mMIMO AAU footprints in the industry, offering substantial OpEx savings.
In addition to the current O-RAN 7.2b specification, the products are also engineered to support ULPI (Uplink Performance Improvement), allowing network operators to improve uplink performance of massive MIMO, minimize latency, and reduce fronthaul bandwidth, especially in urban settings where network capacity demand is high.
The portfolio consists of two discrete models that accelerate 5G mid-band rollouts:
- 32TRX AAU low power model: Offering one of the lowest footprints in the industry, the low power mMIMO AAU delivers 200W output power with 128 antenna elements at the lowest energy consumption. The solution is optimized for deployment in dense environments, driving faster installations and lower operational overheads.
- 32TRX AAU high power model: Mavenir’s high-performance mMIMO AAU capable of delivering 320W output power and offering 192 antenna elements. This platform supports larger instantaneous bandwidth, while the output power extends coverage, making it ideal for RAN sharing deployments.
The 32TRX AAU solutions deliver advanced energy-saving capabilities incorporating smart sleep-mode schemes that are activated during idle, low, and busy hour traffic. These automated capabilities can be further enhanced using AI/ML-based intelligence.
Paco Martin, Head of Open RAN at Vodafone Group: “We are pleased to see the broadening of Mavenir’s mMIMO portfolio with the addition of a low power, compact product fitting our single-operator and footprint-constrained sites, on top of the existing higher power leading solution. Further adoption of Qualcomm QRU100 5G RAN Platform keeps bringing high performance and power efficient Open RAN radios allowing us to deliver the best customer experience.”
BG Kumar, President, Access Networks, Platforms and MDE from Mavenir said: “With this continuing evolution and enhancement of our OpenBeam™ massive MIMO radio solutions, Mavenir is once again setting new standards in the industry for energy efficiency, sustainability and performance.”
“We are very pleased with this extension to Mavenir’s portfolio of high performing and power efficient Massive MIMO Radios, powered by Qualcomm QRU100 5G RAN Platform,” said Gerardo Giaretta, Vice President, Product Management, Qualcomm Technologies, Inc. “This is another great milestone in our ongoing collaboration with Mavenir, driving full-scale adoption of Open and Virtualized RAN.”
Mavenir’s OpenBeam™ full radio portfolio will be displayed at the upcoming Mobile World Congress in Barcelona, Feb 26-29, in Hall 2 Stand 2H60. For more on Mavenir’s presence at the show visit www.mavenir.com/mwc-2024
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 300+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
For more information, please visit www.mavenir.com
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240219034877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom